Usana Health Sciences, Inc. (USNA)
USANA Health Sciences Q2 Earnings Call Highlights
USANA Health Sciences NYSE: USNA said its core nutritional business remained in line with expectations during the second quarter of 2026, while near-term challenges at its Hiya and Rise Wellness ventures led the company to lower its full-year outlook.
USANA Health Sciences: No Clear Growth Engine Left (Rating Downgrade)
USANA Health Sciences, Inc. stock fell sharply after Q2 earnings. The direct selling business has continued to shrink at quite a predictable pace. USNA's two growth brands, Hiya and Rise Wellness, showed a concerning performance. Revenues plummeted, and the brands' 2026 guidance was cut massively.
USANA Health Sciences, Inc. (USNA) Q2 2026 Earnings Call Transcript
USANA Health Sciences, Inc. (USNA) Q2 2026 Earnings Call Transcript
USANA Health Sciences (USNA) Reports Q2 Loss, Lags Revenue Estimates
USANA Health Sciences (USNA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.43. This compares to earnings of $0.74 per share a year ago.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy
USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2.
Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USNA or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?
USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock?
USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript
USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript
